Frontoparietal Priority Maps as Biomarkers for MTBI
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT02251002|
Recruitment Status : Completed
First Posted : September 26, 2014
Last Update Posted : March 21, 2019
|Condition or disease|
|TBI (Traumatic Brain Injury) Ocular Motility Disorders|
|Study Type :||Observational|
|Actual Enrollment :||88 participants|
|Official Title:||Frontoparietal Priority Maps as Biomarkers for MTBI|
|Actual Study Start Date :||July 2015|
|Actual Primary Completion Date :||February 2018|
|Actual Study Completion Date :||October 2018|
no history of TBI or neurologic disorder
documented past mild to moderate TBI
- oculomotor performance [ Time Frame: study enrollment / baseline ]Oculomotor performance will be measured with behavioral questionnaires, eye-charts, and computerized eye-tracking while subjects perform saccades and smooth pursuit motions.
- frontoparietal priority maps [ Time Frame: baseline ]Functional MRI data will be collected at 7 Tesla while subjects perform spatial attention and eye movement tasks.
- white matter integrity [ Time Frame: baseline ]Diffusion tensor imaging data will be acquired at 7 Tesla and analyzed in a priori regions of interest adjacent to frontal and parietal functional regions of interest.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02251002
|Principal Investigator:||Cheryl A Olman, PhD||University of Minnesota|